Wesley M. Jackson (Chief Science Officer) has been actively involved in biotechnology entrepreneurship for nearly a decade. His postdoctoral research at the National Institutes of Health resulted in an issue patent for a novel biological therapy to promote tissue regeneration. Wesley has been the chief science officer at Valitor since 2012, and the principle investigator of three NIH grants to evaluate multivalent conjugates as drugs to accelerate wound healing.
Kevin E. Healy has over 20 years of research experience developing biomimetic materials to actively direct the behavior of cells and facilitate regeneration of tissues and organs. Kevin has previously pursued the development of these technologies by founding BioEngineered Materials, Inc. and Cardiomimetics, Inc. He continues to maintain active collaborations with clinicians in a variety of medical specialties to facilitate the clinical translation of biomedical technologies, and he is a consultant to the biotechnology industry.
David V. Schaffer has over 12 years of academic research with specific expertise in molecular engineering of biologics-based, gene and stem cell therapeutics for tissue regeneration. David has leveraged his experience into more than 12 biotechnology patents, and he is currently engaged in the preclinical and clinical development of these technologies.